BioCentury
ARTICLE | Financial News

Amgen beats Street, raises guidance

October 24, 2012 1:20 AM UTC

Amgen Inc. (NASDAQ:AMGN) increased its full-year revenue and EPS guidance after reporting a 3Q12 adjusted diluted EPS of $1.67, beating the Street's estimate by $0.20 and up 19% from $1.40 in 3Q11. Third quarter revenues grew 10% to $4.3 billion, slightly above the Street's estimate of $4.25 billion. Amgen now expects total revenues of $17.2-$17.3 billion and adjusted EPS of $6.50-$6.60. The company previously forecast revenues of $16.9-$17.2 billion and adjusted EPS of $6.20-$6.35. ...